Emmaus Life Sciences: Mid-Year Financial Update
Emmaus Life Sciences, Inc. (OTC Markets: EMMA), a biopharmaceutical company focused on treatments for sickle cell disease, has released an update on its financial performance through the middle of the year. The report covers results as of June 30, 2024 and provides context on recent operations, costs, and outlook.
Key Takeaways
Management noted a mixed picture. After nearly 61% year-over-year growth in net revenues from 2022 to 2023, the first half of 2024 saw a 55% decline. The company attributed the downturn primarily to a prolonged inventory shortage that began in February, followed by additional supply interruptions from mid-June into August. Chairman and CEO Willis Lee said that production has resumed, but he does not expect full-year net revenues to reach 2023 levels.
Supply Chain Pressures and Response
To reduce the risk of future stockouts, Chief Commercial Officer George Sekulich said Emmaus is working with alternative manufacturers. The team also plans to assess how increased competition, including the launch of a generic L-Glutamine Oral Powder, may affect Endari sales. The immediate priority remains stabilizing supply so customers can reliably access product.
Financial Overview
Net revenues for the six months ended June 30, 2024 were $7.9 million, down from $17.5 million in the same period of 2023. The decrease reflects delays in the production of finished goods. Put simply, when product wasn’t available to ship, revenue fell.
Operating Expenses
Operating expenses for the first half of 2024 totaled $9.5 million, compared with $14.4 million a year earlier. The reduction came from broad-based cuts: general and administrative expenses decreased by $3.4 million, selling expenses by $1.3 million, and research and development by $0.2 million. These savings helped offset part of the revenue shortfall.
Loss from Operations
Emmaus reported a loss from operations of $2.2 million for the first half of 2024. In the first half of 2023, the company recorded income from operations of $2.2 million. The swing reflects the pressure from lower net revenues, partially cushioned by lower operating costs.
Other Expenses
Other expenses were $4.4 million for the current period, down from $7.2 million in the prior-year period. The improvement included a $1.0 million gain on debt restructuring and a $2.5 million reduction in foreign exchange losses. These items narrowed, but did not eliminate, the overall loss.
Net Loss
The net loss for the six-month period was $6.5 million, or $0.10 per share, based on approximately 62.6 million weighted average basic common shares outstanding. That compares with a net loss of $5.0 million in the first half of 2023. The year-over-year change was driven primarily by the decline in revenue tied to supply constraints.
Liquidity
Cash and cash equivalents were $1.5 million as of June 30, 2024, down from $2.5 million at the end of the prior year. The decrease highlights the importance of closely monitoring cash flow while the company works through supply normalization and a more competitive market backdrop.
About Emmaus Life Sciences
Emmaus Life Sciences focuses on therapies for sickle cell disease. Its product Endari (L-glutamine oral powder) is FDA-approved for patients five years of age and older to help reduce acute complications linked to the disease. The company’s work centers on improving day-to-day management for people living with sickle cell.
Endari at a Glance
Approved in July 2017, Endari is used to help lower the frequency of painful crises in sickle cell disease. Emmaus continues to position Endari within current treatment options and to support access and continuity of therapy—especially important given the recent supply challenges.
Frequently Asked Questions
What did Emmaus report for the first half of 2024?
Emmaus reported net revenues of $7.9 million for the six months ended June 30, 2024, down from $17.5 million in the same period of 2023. The period also included a loss from operations of $2.2 million and a net loss of $6.5 million, or $0.10 per share.
Why did revenues fall so sharply?
The decline was primarily due to a prolonged inventory shortage that started in February, followed by additional supply interruptions from mid-June into August. Production has resumed, but management does not expect full-year net revenues to match 2023.
How is the company addressing supply disruptions?
Emmaus is working with alternative manufacturers to reduce the risk of future shortages and improve product availability. The company is also assessing the potential impact of increased competition, including a generic L-Glutamine Oral Powder, on Endari sales.
What changed in operating and other expenses?
Operating expenses fell to $9.5 million from $14.4 million, reflecting lower general and administrative, selling, and R&D costs. Other expenses decreased to $4.4 million from $7.2 million, aided by a $1.0 million gain on debt restructuring and a $2.5 million reduction in foreign exchange losses.
What does the liquidity position look like?
Cash and cash equivalents were $1.5 million at June 30, 2024, compared with $2.5 million at the prior year-end. The company highlighted the need to closely manage cash as it works through supply recovery and a more competitive environment.
